Literature DB >> 32165116

Neoadjuvant Leuprolide Therapy with Radical Prostatectomy: Long-term Effects on Health-related Quality of Life.

Michael C Chen1, Patrick S Kilday1, Peter A Elliott1, Daniel Artenstein1, Jeff Slezak2, Steven J Jacobsen2, Gary W Chien3.   

Abstract

BACKGROUND: Neoadjuvant androgen ablation (neoadjuvant androgen deprivation therapy [NADT]) is used prior to radical prostatectomy, contrary to guidelines, but its long-term effects on quality of life is unknown.
OBJECTIVE: To determine the effect of NADT on patient's long-term recovery following surgery. DESIGN, SETTING, AND PARTICIPANTS: From March 2011 to August 2013, 5808 men with newly diagnosed prostate were followed up to 24 mo. A cohort of men who received NADT prior to robotic-assisted laparoscopic prostatectomy (RALP; n=51) was compared 1:3 with a matched group that underwent RALP only (n=153). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were matched on Charlson comorbidities, biopsy Gleason score, and node status on final pathology. The Kruskall-Wallis test was used to compare the groups on their bowel, urinary, sexual, and hormonal domains of the 26-item Expanded Prostate Cancer Index Composite at baseline and at 1, 3, 6, 12, 18, and 24 mo postoperatively. RESULTS AND LIMITATIONS: The urinary irritative, urinary incontinence, and bowel domains were similar in the two groups during the 24 mo (p=0.832, 0.901, and 0.732, respectively). In the hormonal domain, the NADT group did worse (p<0.001). The sexual domain was also worse for the NADT group. However, when accounting for nerve sparing, there was no significant difference in sexual outcomes between the two groups (p=0.069).
CONCLUSIONS: Patients who received NADT prior to RALP do not have worse sexual function, but have worse hormonal scores for up to 2yr after surgery. PATIENT
SUMMARY: Neoadjuvant androgen deprivation therapy (NADT) is administered prior to robotic-assisted laparoscopic prostatectomy (RALP), contrary to clinical guidelines. NADT may not have worse sexual function outcomes up to 2yr after RALP.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Neoadjuvant therapy; Prostate cancer; Quality of life; Robotic surgical procedures

Mesh:

Substances:

Year:  2020        PMID: 32165116     DOI: 10.1016/j.euf.2020.03.001

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  4 in total

1.  UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Authors:  Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

2.  Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital.

Authors:  Premsant Sangkum; Kun Sirisopana; Pocharapong Jenjitranant; Kittinut Kijvikai; Suthep Pacharatakul; Charoen Leenanupunth; Wachira Kochakarn; Wisoot Kongchareonsombat
Journal:  Res Rep Urol       Date:  2021-06-01

3.  Impacts of Neoadjuvant Hormonal Therapy Prior to Robot-Assisted Radical Prostatectomy on Postoperative Hormonal- and Sexual-Related Quality of Life - Assessment by Patient-Reported Questionnaire.

Authors:  Soichiro Ogawa; Akihisa Hasegawa; Shunta Makabe; Akifumi Onagi; Kanako Matsuoka; Emina Kayama; Tomoyuki Koguchi; Junya Hata; Yuichi Sato; Hidenori Akaihata; Masao Kataoka; Nobuhiro Haga; Yoshiyuki Kojima
Journal:  Res Rep Urol       Date:  2022-02-19

4.  The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Authors:  Lijin Zhang; Hu Zhao; Bin Wu; Zhenlei Zha; Jun Yuan; Yejun Feng
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.